Homogeneous Opioid Trial Populations Could Simplify, Improve Data – Cmte
Executive Summary
Limiting opioid trial populations to specific pain syndromes could improve safety and efficacy evaluations of the analgesics, FDA's Anesthetic & Life Support Drugs Advisory Committee suggested
You may also be interested in...
Opioid Analgesic Risk Management Should Not Inhibit Access, Cmte. Says
Risk management plans for opioid analgesics should be modified if it appears the plan inhibits access for the appropriate patient population, FDA's Anesthetic & Life Support Drugs Advisory Committee said
Opioid Analgesic Risk Management Should Not Inhibit Access, Cmte. Says
Risk management plans for opioid analgesics should be modified if it appears the plan inhibits access for the appropriate patient population, FDA's Anesthetic & Life Support Drugs Advisory Committee said
Opioid Analgesic Chronic Pain Studies Pose Challenge For FDA
FDA will be asking the Anesthetic & Life Support Drugs Advisory Committee for input into the appropriate inclusion criteria for studies of opioid analgesics in chronic pain.